CAAS
RDHL

Capital Asset Advisory Services’s Redhill Biopharma RDHL Stock Holding History

Capital Asset Advisory Services’s Portfolio RDHL Stock Details RDHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-29
Closed -$132K – 686
2021
Q3 		$132K Buy
+29
New +$197K 0.01% 440

Other funds holding RDHL

DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $837M AUM 25.51% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Capital Asset Advisory Services's RDHL Position: Q4 2021 in Review

Capital Asset Advisory Services sold out of Redhill Biopharma (RDHL) in Q4 2021, closing a stake of 29 shares — an estimated $132K sold.

Capital Asset Advisory Services first reported a position in RDHL in Q3 2021 and held it in 1 quarter. The position peaked at $132K in Q3 2021. 51 funds tracked by Wall St. Rank hold RDHL as of Q4 2021.

  • Capital Asset Advisory Services reported no remaining Redhill Biopharma position as of Q4 2021 after selling out during the quarter.
  • Capital Asset Advisory Services sold 29 Redhill Biopharma shares in Q4 2021, an estimated $132K.
  • Capital Asset Advisory Services first reported a position in Redhill Biopharma in Q3 2021 and held it in 1 quarter.
  • Capital Asset Advisory Services's Redhill Biopharma position peaked at $132K in Q3 2021.
  • 51 funds tracked by Wall St. Rank held Redhill Biopharma as of Q4 2021.

Based on Capital Asset Advisory Services's 13F filing for Q4 2021, filed 4 Feb 2022.